Investigating DNA changes in colorectal cancer patients
Novel DNA Adductomics Methodological Developments for Research in Colon Cancer
This study is trying to find out if certain DNA changes in colon tissue and other samples can help us understand why some people get colorectal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Copenhagen Academic / other |
| Locations | 1 site (Copenhagen, Frederiksberg C) |
| Trial ID | NCT04865601 on ClinicalTrials.gov |
What this trial studies
This project aims to identify DNA adducts in colon tissue from patients with colorectal cancer (CRC) who are scheduled for colon resections, as well as from control patients undergoing similar procedures. The study will also analyze surrogate samples such as white blood cells, blood plasma, and urine for DNA-repair products. By utilizing advanced high-resolution mass spectrometry, the research seeks to understand the genetic modifications associated with increased CRC risk, particularly focusing on sporadic cases and hereditary conditions like Lynch syndrome and familial adenomatous polyposis. This approach aims to fill the knowledge gap regarding the relationship between DNA adducts and CRC development.
Who should consider this trial
Good fit: Ideal candidates include patients with familial adenomatous polyposis, Lynch syndrome, hereditary non-polyposis colorectal cancer, sporadic colorectal cancer, or ulcerative colitis who are scheduled for colon resection.
Not a fit: Patients under 18 years of age or those who have recently donated blood may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of the genetic factors contributing to colorectal cancer, potentially guiding prevention and treatment strategies.
How similar studies have performed: Previous studies have identified DNA adducts in colorectal cancer using older technologies, but this study employs a novel approach with advanced mass spectrometry, making it a potentially groundbreaking investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with either FAP, Lynch syndrome, other HNPCC, sporadic colorectal cancer, ulcerative colitis or other conditions who are scheduled for whole or partial resection of their colon Exclusion Criteria: * Any condition that makes the investigator or hospital personnel doubt that voluntary participation isfeasible. * Patients who are not able to understand and sign the informed consent form for any reason, including lack of a sufficient period of time to consider their participation. * Patients who are below 18 years of age. * Patients who donated blood to a blood bank within 3 months prior to their operation.
Where this trial is running
Copenhagen, Frederiksberg C
- Department of Nutrition, Exercise and Sports, University of Copenhagen — Copenhagen, Frederiksberg C, Denmark (Recruiting)
Study contacts
- Principal investigator: Lars Ove O Dragsted, PhD — University of Copenhagen
- Study coordinator: Lars Ove Drasted, professor
- Email: ldra@nexs.ku.dk
- Phone: +4535332694
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.